HLA Variation and SARS-CoV-2 Specific Antibody Response
Viruses · 2023
DOI: 10.3390/v15040906 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Dawit Wolday und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1Z5, Canada. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Differences in SARS-CoV-2-specific immune responses have been observed between individuals following natural infection or vaccination. In addition to already known factors, such as age, sex, COVID-19 severity, comorbidity, vaccination status, hybrid immunity, and duration of infection, inter-individual variations in SARS-CoV-2 immune responses may, in part, be explained by structural differences brought about by genetic variation in the human leukocyte antigen (HLA) molecules responsible for the presentation of SARS-CoV-2 antigens to T effector cells. While dendritic cells present peptides with HLA class I molecules to CD8+ T cells to induce cytotoxic T lymphocyte responses (CTLs), they present peptides with HLA class II molecules to T follicular helper cells to induce B cell differentiation followed by memory B cell and plasma cell maturation. Plasma cells then produce SARS-CoV-2-specific antibodies. Here, we review published data linking HLA genetic variation or polymorphisms with differences in SARS-CoV-2-specific antibody responses. While there is evidence that heterogeneity in antibody response might be related to HLA variation, there are conflicting findings due in part to differences in study designs. We provide insight into why more research is needed in this area. Elucidating the genetic basis of variability in the SARS-CoV-2 immune response will help to optimize diagnostic tools and lead to the development of new vaccines and therapeutics against SARS-CoV-2 and other infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1Z5, Canada.
- Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G 1Z5, Canada.
ORCID-Profile: Gregory Morgan, Jennifer Taher, Jordan P Lerner-Ellis
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Wolday, D., Fung, C. Y. J., Morgan, G., Casalino, S., Frangione, E., Taher, J., & Lerner-Ellis, J. P. (2023). HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses. https://doi.org/10.3390/v15040906
Vancouver
Wolday D, Fung CYJ, Morgan G, Casalino S, Frangione E, Taher J, et al. HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses. 2023. doi:10.3390/v15040906
BibTeX
@article{Wolday2023,
author = {Wolday, Dawit and Fung, Chun Yiu Jordan and Morgan, Gregory and Casalino, Selina and Frangione, Erika and Taher, Jennifer and Lerner-Ellis, Jordan P},
title = {HLA Variation and SARS-CoV-2 Specific Antibody Response},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15040906}
}
EUVIMED